Name	: Mr. MANAS RANJAN SWAIN (47 /M)	Date : 02/03/2024			
Address	: FLAT NO-503, BLOCK-H, RAIL VIH WEST BENGAL, INDIA	AR, PS-NEW TOWN, KOLKA	TA, KOLKATA,			
Examined	by:		UHID : AGHL.0001469099			
Package	: MEDIWHEEL - FULL BODY ANNUAL I	PLUS WITH TMT MALE HCK	AHC No : AMHLAH198487			
For corporate h	NOWN ILLNESS - Diabetes mellitus,	Skin - Nil Significant Version Past medical histo Covid 19	- Yes			
	Hypertension, Thyroid disorder, Heart disease, Stroke	Hospitalization for Covid 19 Typhoid	- No - yes			
Dyslipidaemia	Medication - regular; - Tonact 10	Personal history				
Asthma	Control - good; Medication - inhalers; - under the care of chest physician	Marital status No. of children Diet Alcohol Smoking Chews tobacco	- Married - 2 - Non Vegetarian - does not consume alcohol - No - No			
Cardiovascula	r system	Physical activity	- Mild			
- Nil Significant	-	+ Eamily history				
Respiratory sy	rstem	Family history	her eveloped			
Sneezing - on and off; Exacerbated by - allergens		Mother	- has expired - alive			
Gastrointestin - Nil Significant	-	Diabetes Coronary artery disease	- father - mother			
Genitourinary - Nil Significant	-	Cancer PHYSICAL EXAMINA	- None			
- Nil Significant	-	General				
Eyes Vision - normal ENT	with glasses; Glasses - yes	Build Height Weight BMI	- over weight - 166 - 74 - 26.85			
- Nil Significant		Pallor	- 20.85 - No			
-		Oedema	- no			
Musculoskelet Spine and joint	-	Cardiovascular system				

Heart rate (Per minute)

Rhythm

- 88

- Regular

- Nil Significant

UHID : AGHL.0001469099

Date : 02/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No: AMHLAH198487

	- B.P. Sitting
Systolic(mm of Hg)	- 126
Diastolic(mm of Hg)	- 94
Heart sounds	- S1S2+

Respiratory system

Breath sounds

- Normal vesicular breath sounds



Appearance

Tenderness

Organomegaly

- Normal - No

- No

Printed By : Benazir Begaum

Date : 02/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH198487

COMPLETE HAEMOGRAM PROFILE						
Test Name	Result	Unit Level	Range			
Hemoglobin	14.2	g/dl 📃 🔍	13.0-17.0			
RBC COUNT	6.14 *	Million/ 🗕 ul	4.5-5.5			
Hematocrit - Hct:	45.4	%	41-53			
MCV	74.0 *	fl 🔴	83-101			
MCH	23.1 *	pg 🔴	27-32			
MCHC	31.2 *	%	31.5-34.5			
RDW	15.1 *	%	11.8-14.0			
WBC Count	7200	/cu mm 🔍	4000-10000			
Platelet Count	1.46 *	lacs/cu ● mm	1.5-4.0			
Neutrophils	53	%	40-80			
Lymphocytes	34	%	20-40			
Monocytes	06	%	2-10			
Eosinophils	07 *	%	01-06			
Basophils	00	%	0-0			
RBC:	Density I Hypochr	Increased, Mic omic.	crocytic			
Platelets:	Adequat	e on the smea	ar			
ERYTHROCYTE SEDIMENTATION RATE (ESR)	2	mm/1st ● hr	0-15			

URINE ROUTINE AND MICROSCOPY

Test Name	Result Unit	Level Range			
Volume:	30 mL				
Colour:	Pale Straw				
Appearance	Clear				
Specific Gravity	1.005				
pH:	6.0				
Albumin:	Not Detected				
Glucose	Not Detected				
Ketone:	Not Detected				
Bile Pigments	Not Detected				
RBC	Nil /hpf				
Pus Cells	Occasionalhpf				

TH TMT MALE HCK		AHC	No : A	MHLAH
Epithelial Cells	Occasio	onalhpf		
Casts:	Not Fou	Ind		
Crystals:	Not Fou	Ind		
URINE SUGAR- FAST	'ING(QU		TIVE)	
Test Name	Result	Unit	Level	Range
URINE GLUCOSE(FASTING)	Nil			
BLOOD GROUPING A		•		
Test Name	Result	Unit	Level	Range
ABO Group:	0			
Rh (D) Type:	POSITI	VE		
LIVER FUNCTION TE	ST (PAC	KAGE)	
Test Name	Result	Unit	Level	Range
ALT(SGPT) - SERUM	25	U/L	•	0-50
ALBUMIN - SERUM	4.3	g/dL	•	3.5-5.1
ALKALINE PHOSPHATASE - SERUM	71	U/L	•	43-115
AST (SGOT) - SERUM	26	U/L	•	0-50
BILIRUBIN TOTAL - SERUM	0.6	mg/dl	•	0.3-1.2
LIPID PROFILE TEST	(PACKA	AGE)		
Test Name	Result	Unit	Level	Range
CHOLESTEROL - SERUM	185	mg/dl	•	0-200
CREATININE - SERUM	И			
Test Name	Result	Unit	Level	Range
CREATININE - SERUM	1.0	mg/dl	-	0.9-1.3
LIVER FUNCTION TE	ST (PAC	KAGE)	
Test Name	Result	Unit	Level	Range
GGTP: GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM	73 *	U/L	•	0-55

Out of Range

Within Normal Range

Borderline High/Low

Name : Mr. MANAS RANJAN SWAIN (47 /M)

UHID : AGHL.0001469099

Date : 02/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH198487

SLOOD ult Unit % KAGE) ult Unit mg	/dL	evel	Nondiadetic : 4 - 5.6 % Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7%	SERUM THYROID PROFILE - Test Name TSH: THYROID STIMULATING HORMONE - SERUM URIC ACID - SERUM Test Name URIC ACID - SERUM IURIC ACID - SERUM EIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL) - SERUM	Result 1.29 Result 6.9 ST (PAC Result 0.1	Unit µIU/m Unit mg/dL KAGE) Unit mg/dL	Level Level Level SA TO	Range 0.38-5.33 Range 2.6-7.2 Range 0.0-0.2 TAL) - Range 0.00-6.50
SLOOD ult Unit % KAGE) ult Unit mg	Le /dL /dL	evel	Range Nondiadetic : 4 - 5.6 % Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	Test Name TSH: THYROID STIMULATING HORMONE - SERUM URIC ACID - SERUM Test Name URIC ACID - SERUM LIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result 1.29 Result 6.9 ST (PAC Result 0.1 C ANTIG Result	Unit µIU/m Unit mg/dL KAGE) Unit mg/dL	Level Level Level SA TO	0.38-5.33 Range 2.6-7.2 Range 0.0-0.2 TAL) - Range
ult Unit % KAGE) ult Unit mg mg	Le /dL (/dL (evel	Nondiadetic : 4 - 5.6 % Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	Test Name TSH: THYROID STIMULATING HORMONE - SERUM URIC ACID - SERUM Test Name URIC ACID - SERUM LIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result 1.29 Result 6.9 ST (PAC Result 0.1 C ANTIG Result	Unit µIU/m Unit mg/dL KAGE) Unit mg/dL	Level Level Level SA TO	0.38-5.33 Range 2.6-7.2 Range 0.0-0.2 TAL) - Range
ult Unit % KAGE) ult Unit mg mg	Le /dL (/dL (evel	Nondiadetic : 4 - 5.6 % Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	STIMULATING HORMONE - SERUM URIC ACID - SERUM Test Name URIC ACID - SERUM LIVER FUNCTION TES Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result 6.9 ST (PAC Result 0.1 C ANTIG Result	Unit mg/dL KAGE) Unit mg/dL GEN (PS Unit	Level Level SA TO	Range 2.6-7.2 Range 0.0-0.2 TAL) - Range
% KAGE) ult Unit mg mg	Le /dL (evel	Nondiadetic : 4 - 5.6 % Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	URIC ACID - SERUM Test Name URIC ACID - SERUM LIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	6.9 ST (PAC Result 0.1 C ANTIG Result	mg/dL CKAGE) Unit mg/dL GEN (PS Unit	Level	2.6-7.2 Range 0.0-0.2 TAL) - Range
KAGE) Jlt Unit mg	Le /dL (/dL (evel	- 5.6 % Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	Test Name URIC ACID - SERUM LIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	6.9 ST (PAC Result 0.1 C ANTIG Result	mg/dL CKAGE) Unit mg/dL GEN (PS Unit	Level	2.6-7.2 Range 0.0-0.2 TAL) - Range
u lt Unit mg mg	Le /dL		Prediabetics : 5.7 - 6.4% Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	URIC ACID - SERUM LIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	6.9 ST (PAC Result 0.1 C ANTIG Result	mg/dL CKAGE) Unit mg/dL GEN (PS Unit	Level	2.6-7.2 Range 0.0-0.2 TAL) - Range
u lt Unit mg mg	Le /dL		Diabetes : >/= 6.5% ADA Theraputic goal : <7% Range 30-70	LIVER FUNCTION TEST Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	ST (PAC Result 0.1 C ANTIG Result	KAGE) Unit mg/dL iEN (PS Unit) Level SA TO	Range 0.0-0.2 TAL) - Range
u lt Unit mg mg	Le /dL		ADA Theraputic goal : <7% Range 30-70	Test Name BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result 0.1 C ANTIG Result	Unit mg/dL GEN (PS Unit	Level SA TO Level	0.0-0.2 TAL) - Range
u lt Unit mg mg	Le /dL		Theraputic goal : <7% Range 30-70	BILIRUBIN CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	0.1 C ANTIG Result	mg/dL GEN (PS Unit	SA TO	0.0-0.2 TAL) - Range
u lt Unit mg mg	Le /dL		: <7% Range 30-70	CONJUGATED (DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	C ANTIG Result	iEN (PS Unit	SA TO	TAL) - Range
u lt Unit mg mg	Le /dL		Range 30-70	(DIRECT) - SERUM PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result	Unit	Level	Range
u lt Unit mg mg	Le /dL		30-70	PROSTATIC SPECIFIC SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result	Unit	Level	Range
mg mg	/dL		30-70	SERUM Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	Result	Unit	Level	Range
mg	/dL	•		Test Name PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)			_	
-			Optimal: <100	PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)			_	
-			Optimal: <100	ANTIGEN (PSA TOTAL)	0.58	ng/mL	•	0.00-6.50
mg	/dL							
			0-35					
				BUN (BLOOD UREA				_
ACKAG	iE)			Test Name	Result			Range
ult Unit		evel	Range	BUN (BLOOD UREA NITROGEN)	11.5	mg/dL	•	7.0-18.0
g/d	L		6.4-8.3	,	ST (PAC	KAGE)	
a/d			1836	Test Name	•			Range
g/u	-	-	1.0-3.0	A/G - RATIO	1.5		•	1.0-2.0
				BUN/CREATININE RA	ΤΙΟ			
		•		Test Name	Result	Unit	Level	Range
		evel		BUN/CREATININE	11.2			
ng/	ml (0.87-1.78	RATIO				
				ECG				
μg/	dL (5.48-14.28	SINUS RHYTHM. LOW VOLTAGE T WAVE	ES.			
KAGE)				TREADMILL TEST / STI	RESS TF	ST		
PROFILE TEST (PACKAGE) Name Result Unit Level Range			Range					
					JK PRO	IVUCA	BLE	
	Γ4 AND ult Unit , μg/ CKAGE) ult Unit	ult Unit Le 3 ng/ml (, _{µg/dL} (CKAGE) ult Unit Le	T4 AND TSH) ult Unit Level β ng/ml ● μg/dL ●	T4 AND TSH) ult Unit Level Range s ng/ml ● 0.87-1.78 µg/dL ● 5.48-14.28 CKAGE) ult Unit Level Range	g/dL ● 1.8-3.6 Test Name A/G - RATIO BUN/CREATININE RA Test Name BUN/CREATININE RA BUN/CREATININE RATIO Free Stress Test is NEG/ MYOCARDIAL ISCHAEL	g/dL 1.8-3.6 Test Name Result A/G - RATIO 1.5 F4 AND TSH) BUN/CREATININE RATIO ult Unit Level Range ng/ml 0.87-1.78 BUN/CREATININE 11.2 r µg/dL 5.48-14.28 SINUS RHYTHM. LOW VOLTAGE T WAVES. CKAGE) ult Unit Level ult Unit Level Range	g/dL 1.8-3.6 Test Name Result Unit A/G - RATIO 1.5 1.5 T4 AND TSH) BUN/CREATININE RATIO Result Unit uit Unit Level Range 0.87-1.78 mg/ml 0.87-1.78 ECG SINUS RHYTHM. UW VOLTAGE T WAVES. TREADMILL TEST / STRESS TEST CKAGE) TREADMILL TEST / STRESS TEST uit Unit Level	A/G - RATIO 1.5 A/G - RATIO 1.5 BUN/CREATININE RATIO Test Name Result Unit Level BUN/CREATININE 11.2 RATIO Fest Name Result Unit Level BUN/CREATININE 11.2 RATIO ECG SINUS RHYTHM. LOW VOLTAGE T WAVES. TREADMILL TEST / STRESS TEST STRESS TEST IS NEGATIVE FOR PROVOCA MYOCARDIAL ISCHAEMIA.

Date : 02/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH198487

ULTRASOUND SCREENING WHOLE ABDOMEN

* Grade I fatty liver.

[NOTE: At times pelvic structures are not well visualized due to inadequate patient preparation / excess bowel gas shadow. However suggested clinical correlation and other investigations if clinically indicated.

Dr. ARKADEEP DEY DNB RESIDENT In consultation with

X-RAY CHEST PA

*Right dome of diaphragm is elevated - needs evaluation.

INVESTIGATIONS NOT DONE / NOT YET REPORTED / NOT PART OF PACKAGE(LAB,RADIOLOGY & CARDIOLOGY)

Haematology

URINE SUGAR - POST PRANDIAL (QUALITATIVE)

Biochemistry

GLUCOSE - PLASMA (POST PRANDIAL)





Out of Range

Date : 02/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH198487

Printed By :

AHC Physician / Consultant Internal Medicine

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases. UHID : AGHL.0001469099

Date : 02/03/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No : AMHLAH198487

AICVD RISK SCORE REPORT							
RISK STATUS	YOUR SCORE	ACCEPTABLE SCORE					
Low Risk	5	6					

Your cardiovascular disease risk in the next 10 years is within the Normal limits for your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence -based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with **medications** for high blood pressure, diabetes, or dyslipidemia, if advised by your physician. Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.
- Follow your physician's advice regarding follow up tests, consults and annual health assessment

DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging, treatment or patient education related to lifestyle management is under the physician 's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side .
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

The Clinical AI Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515